阿根廷生物技术公司Inmunova正在开发一种可能成为首种针对溶血性尿毒综合征的特异性治疗药物，该疾病主要影响儿童。该药物目前处于临床开发阶段，若获批将成为全球首创。
Argentine biotech firm Inmunova is developing what could become the first specific treatment for haemolytic uraemic syndrome, a disease that mainly affects children. The drug is currently in clinical development and would be a global first if approved.
总部位于布宜诺斯艾利斯的生物技术公司Inmunova正在研发一种实验性药物，靶向溶血性尿毒综合征——一种主要侵袭幼儿并可能导致严重肾脏损伤的疾病。
Buenos Aires-based biotech firm Inmunova is developing an experimental drug targeting haemolytic uraemic syndrome, a disease that mainly strikes young children and can cause severe kidney damage.
该公司的药物目前正在推进临床开发。若获批，它将成为全球首款专门针对该疾病的治疗药物——目前医生只能为患者提供支持性护理。
The company's drug is currently moving through clinical development. If approved, it would become the world's first treatment specifically targeting the disease — doctors currently can only offer supportive care to patients.
这一发展凸显了阿根廷在生物技术领域日益增长的科研实力及其在全球罕见病药物研发中的日益重要作用。
The development highlights Argentina's growing research capacity in biotechnology and its expanding role in global drug development for rare diseases.